Step by Step


2016-09-13 - Medical Grand Rounds: Immune Mechanisms in the Tumor Microenvironment & The 4th modality has arrived - Immunotherapy for Cancer





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Evaluate immune system cells and targets that mediate tumor escape and tumor progression.
  • Recognize therapeutic strategies targeting suppressive cells and receptor pathways to reverse immune escape.
  • Assess initial efficacy data from recent clinical trials of cancer immunotherapy.

Presentation Topics
Title:  Immune Mechanisms in the Tumor Microenvironment
Presenter:  Dario Vignali, PhD

Title:  The 4th modality has arrived - Immunotherapy for Cancer
Presenter:  Robert L. Ferris, MD, PhD

Suggested Additional Reading:

  1. JI-CE (2002)169:5392
  2. JI (2005) 174:688
  3. EMBOJ (2007) 26:494.
  4. Nature (2007) 450:566
  5. JI (2009) 182:6121
  6. Nature Immunology (2010) 11:1093
  7. Nature Immunology (2012) 13:290.
  8. Nature (2013) 501:252.
  9. Vignali et al (2008) Nature Reviews Immunology 8, 523.
  10. Galon et al. Science,2006;313:1960-1964
  11. Mellman I et al. Nature,2011;480:480-489.

Dario Vignali, PhD — Professor & Vice Chair of Immunology Co-Leader of the Cancer Immunology Program Co-Director of the Tumor Microenvironment Center University of Pittsburgh Department of Immunology
Dr. Vignali receives grant/research support, Potenza Therapeutics, Tizona Therapeutics. A Consultant with Potenza Therapeutics, Tizona Therapeutics, Oncorus, Pieris, Moderna, Opexa and stockholder with Potenza Therapeutics, Tizona Therapeutics and Oncorus.
Robert L. Ferris, MD, PhD — UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology Professor of Immunology and Radiation Oncology Co-leader, Cancer Immunology Program
Dr. Ferris receives grant/research support from Astra-Zeneca; BMS; Merck; VentiRx Pharmaceuticals. He also a member of the Advisory Board for Astra-Zeneca/MedImmune; BMS; Lilly; Merck; Pfizer.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.